Anti-hTNF-α-hIgG4
-
Cat.code:
htnfa-mab4
- Documents
ABOUT
Human IgG4 monoclonal antibody (mAb) against human TNF-α
Anti-hTNF-α-hIgG4 is a neutralizing monoclonal antibody (mAb) featuring the constant region of the human IgG4 (hIgG4) isotype and the variable region of adalimumab, a fully human therapeutic mAb that targets human tumor necrosis factor-alpha (hTNF-α). The variable region of adalimumab blocks the interaction of soluble and membrane-bound TNF-α with its receptors TFNR1 and TNFR2, thereby downregulating the inflammatory responses [1,2].
Anti-hTNF-α-hIgG4 was generated by recombinant DNA technology. It is produced in CHO cells and purified by affinity chromatography with protein G. The neutralizing activity of Anti-hTNF-α-hIgG4 was determined using recombinant human TNF-α and HEK-Blue™ TNF-α cells. TNF-α is a pleiotropic cytokine that notably induces NF-κB-mediated production of pro-inflammatory cytokines [1,2].
Human IgG4 Isotype:
The human IgG4 isotype displays low to no potency for Fc-mediated antibody-dependent cellular cytotoxicity (ADCC), low potency for antibody-dependent cellular phagocytosis (ADCP), and it does not mediate complement-dependent cytotoxicity (CDC).
Read our flyer on Clinically relevant monoclonal antibodies and antibody isotype effector functions.
References:
1. Steeland S., et al. 2018. A new venue of TNF targeting. Int. J. Mol. Sci. 19:1442.
2. Shealy D.J. & Visvanathan S. 2008. Anti-TNF antibodies: lessons from the past, roadmap for the future. Therapeutic Antibodies (book). 101-129.
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
Sodium phosphate buffer, glycine, saccharose, stabilizing agents
Neutralization assay, ELISA, Fc interaction studies
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hTNF-α-hIgG4
-
Cat code:htnfa-mab4
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20 °C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Tumor necrosis factor-alpha (TNF-α) is a pleiotropic cytokine involved in necrotic and apoptotic cell death, cellular differentiation, inflammation, and regulation of immune cell activity [1]. TNF-α is mainly produced by activated monocytes, macrophages, and T cells. It is first synthesized as a membrane-bound molecule that forms a compact homotrimer through non-covalent interactions. The trimeric membrane-bound form is cleaved by tumor necrosis factor-alpha converting enzyme (TACE) releasing the soluble trimer [2]. Both the membrane-bound and soluble TNF-α bind homotrimeric transmembrane receptors, TNFR1 or TNFR2, triggering signaling pathways that involve TRADD, TRAF2, and RIP, and leading to the activation of NF-κB and MAPK pathways. Importantly, membrane-bound TNF can also mediate a reverse "outside-to-inside" signaling, although this mechanism remains to be fully elucidated [2].
References:
1. Steeland S., et al. 2018. A new venue of TNF targeting. Int. J. Mol. Sci. 19:1442.
2. Shealy D.J. & Visvanathan S. 2008. Anti-TNF antibodies: lessons from the past, roadmap for the future. Therapeutic Antibodies (book). 101-129.
DOCUMENTS
Documents
Technical Data Sheet
Safety Data Sheet
Validation Data Sheet
Certificate of analysis
Need a CoA ?